IMUC

AcronymDefinition
IMUCInstituto Metodista Universitario Crandon (Uruguayan university)
IMUCIncorporated Militia of Upper Canada (military reenactment; Ontario, Canada)
IMUCIncident Management Unified Command (course)
References in periodicals archive ?
ImmunoCellular Therapeutics (NYSE MKT: IMUC), a company involved in the research, development and commercialisation of novel cancer vaccines, has received approval from regulatory authorities in Canada, the UK and the Netherlands to commence the ICT-107 phase three registration trial in newly diagnosed glioblastoma, it was reported yesterday.
ImmunoCellular Therapeutics (NYSE MKT: IMUC), a company involved in the research, development and commercialisation of novel cancer vaccine, has received a USD19.9m grant from The California Institute for Regenerative Medicine, it was reported on Friday.
Clinical-stage company ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC) reported on Wednesday the addition of Dr Anthony J Gringeri PhD as senior vice president of its Strategic Resources.
5 October 2011 - Progenitor Cell Therapy LLC, or PCT, a subsidiary of NeoStem Inc (AMEX:NBS), and ImmunoCellular Therapeutics Ltd (OTCBB:IMUC) said on Monday that IMUC has retained the services of PCT to serve as the second production site to produce ICT-107, a dendritic cell-based vaccine targeting multiple tumour associated antigens for glioblastoma, for its Phase II study.
As part of the deal, PCT will transfer and qualify the cGMP manufacturing process for ICT-107 at PCT's West Coast facility in Mountain View, California for use in IMUC's US-based Phase II clinical trial, as well as subsequent manufacturing to support future studies and development efforts.
5 October 2010 - US-based biotechnology company ImmunoCellular Therapeutics (OTCBB: IMUC) today announced that clinical data on ICT-107, the company's lead cancer stem cell-targeting vaccine for the treatment of glioblastoma multiforme (GBM), were presented in two oral sessions at the World Stem Cell Summit, which is being held October 4-6 in Detroit, MI.
20 January 2010 - US ImmunoCellular Therapeutics Ltd (OTC: IMUC) reported today the results of a study in which it was shown that certain specific antigens are highly expressed on cancer stem cells (CSCs).
The CSCs used in IMUC's study were isolated from the tumours of five patients with glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.